drugset / Trial / NCT07142356

A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension

NCT07142356 ↗

Phase 2 Recruiting 280 enrolled Retension Pharmaceuticals. Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The goal of this clinical trial is to learn if the drug RT-001 works to reduce high blood pressure (hypertension) in adults. It will also learn about the safety of RTN-001. The main questions it aims to answer are: Does RTN-001 lower blood pressure in patients who have uncontrolled hypertension? What medical problems do participants have when taking RTN-001? Researchers will compare RTN-001 to a placebo (a look-alike substance that contains no drug) to see if RTN-001 works to treat uncontrolled hypertension. Participants will: Take RTN-001 or a placebo every day for 12 weeks Visit the clinic about once every 2 weeks for checkups and tests Keep a diary of their symptoms and all medications that they take including RTN-001

Timeline

Start
2025-10-31
Primary completion
2026-10
Completion
2027-05

Drugs

EvaluationDrugModalityDoseRoute
Subject RTN-001 Unknown 15 mg Oral
Subject RTN-001 Unknown 30 mg Oral
Subject RTN-001 Unknown 45 mg Oral

Indications